July 02, 2014
1 min read

Severe anaphylaxis accounted for 22% of anaphylaxis cases requiring ED visits, hospitalizations

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Almost one-quarter of ED visits or hospitalizations for anaphylaxis involved severe anaphylaxis, while preventive care the year before the event lowered that risk, according to recent study results.

Researchers used an expanded ICD-9-CM diagnosis algorithm to identify 11,927 patients (median age, 45 years; 58% female) from two databases who had an ED visit or hospitalization for anaphylaxis between 2002 and 2008. The patients had continuous medical and prescription coverage for at least 1 year before and after the event. Reaction requiring hospital admission was used to define severe anaphylaxis.

Twenty-two percent of patients had severe anaphylaxis, which was associated with older age and higher comorbidity burden, according to unadjusted analysis.

“These patients were also less likely to have filled an epinephrine autoinjector (EAI) prescription or visited an allergist/immunologist, but more likely to have had an ED visit/hospitalization (any cause),” the researchers wrote.

Reduced risk for severe anaphylaxis was associated with filling an EAI prescription (OR=0.64; 95% CI, 0.53-0.78) or visiting an allergist/immunologist (OR=0.78; 95% CI, 0.63-0.95) before the ED visit or hospitalization, while higher risk for severe anaphylaxis was associated with any previous ED visit (OR=1.18; 95% CI, 01.07-1.3) or hospitalization (OR=1.55; 95% CI, 1.36-1.75), according to multivariable analysis.

“Preventive anaphylaxis care in the year before the index event was associated with a significantly lower risk of severe anaphylactic reaction,” the researchers concluded. “These retrospective data support the benefits of preventive anaphylaxis in real-world practice.”

Disclosure: See the study for a full list of relevant financial disclosures.